These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31818164)

  • 1. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
    Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
    J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
    [No Abstract]   [Full Text] [Related]  

  • 2. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
    Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
    J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
    [No Abstract]   [Full Text] [Related]  

  • 3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
    Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
    J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-cause and disease-related health care costs associated with recurrent venous thromboembolism.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Hossou Y; Schein J; Kaatz S
    Thromb Haemost; 2013 Dec; 110(6):1288-97. PubMed ID: 24085327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
    Casciano JP; Dotiwala Z; Kemp R; Li C; Cai J; Preblick R
    Am J Health Syst Pharm; 2015 Feb; 72(4):291-300. PubMed ID: 25631836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
    Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
    Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
    Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
    Khorana AA; McCrae KR; Milentijevic D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J
    Support Care Cancer; 2019 Oct; 27(10):3833-3840. PubMed ID: 30734088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
    Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
    Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs of patients with cancer stratified by Khorana score risk levels.
    Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
    J Med Econ; 2021; 24(1):866-873. PubMed ID: 34181497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.